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Introduction {#j_raon-2017-0019_s_001}
============

Although the standard treatment for malignant gliomas is the combination of maximal resection followed by radiation therapy and adjuvant chemotherapy (temozolomide)^[@j_raon-2017-0019_ref_001]^, their prognosis remains unfavorable. Maximal resection is the most important factor for improving the survival rate^[@j_raon-2017-0019_ref_002]-[@j_raon-2017-0019_ref_004]^, patients who underwent complete resection benefited more from temozolomide than did patients treated by incomplete resection.^[@j_raon-2017-0019_ref_005]^

According to the 2016 WHO classification, the genetic profile, *e*.*g*. the isocitrate dehydrogenase 1 (IDH1) mutation status and 1p19q co-deletion, is the key factor for the diagnosis and treatment of diffuse gliomas. The IDH1 mutation status is more prognostic for overall survival than are standard histological criteria that differentiate high-grade astrocytomas.^[@j_raon-2017-0019_ref_006],[@j_raon-2017-0019_ref_007]^ Also, the prognosis of IDH1 mutant glioblastoma is considerably better than of IDH1 wild-type anaplastic astrocytoma and glioblastoma^[@j_raon-2017-0019_ref_006],[@j_raon-2017-0019_ref_007]^, and methylation of the O-6-methylguanine DNA methyltransferase (MGMT) promoter in diffuse gliomas is a predictive epigenetic marker of the responsiveness to alkylating agents such as temozolomide.^[@j_raon-2017-0019_ref_008]^

A naturally occurring intermediary in the heme synthetic pathway, 5-aminolevulinic acid (5-ALA)^[@j_raon-2017-0019_ref_009]^, is used for the intraoperative visualization of malignant gliomas. After its administration as a prodrug, it is metabolized at the tissue level to the active compound, protoporphyrin IX (PPIX), which is responsible for *in vivo* photosensitization.^[@j_raon-2017-0019_ref_009]^ 5-ALA-induced fluorescence guidance facilitates complete tumor removal and may enhance progression-free survival.^[@j_raon-2017-0019_ref_004],[@j_raon-2017-0019_ref_010]^ According to previous studies^[@j_raon-2017-0019_ref_009],[@j_raon-2017-0019_ref_011]^, no visible fluorescence was reported in 100% of World Health Organization (WHO) grade I, 81% of WHO grade II, and 25% of high-grade (WHO grades III and IV) gliomas. High-grade gliomas lacking contrast enhancement on magnetic resonance imaging (MRI) scans may not display appreciable macroscopic fluorescence.^[@j_raon-2017-0019_ref_012]^

In contrast, it has been reported that 5-ALA-induced fluorescence is associated with contrast enhancement on preoperative MRI scans^[@j_raon-2017-0019_ref_013]^, a high-grade WHO classification^[@j_raon-2017-0019_ref_014]-[@j_raon-2017-0019_ref_016]^, high tumor cellularity^[@j_raon-2017-0019_ref_017]-[@j_raon-2017-0019_ref_019]^, an increased MIB-1 labeling index^[@j_raon-2017-0019_ref_012],[@j_raon-2017-0019_ref_015],[@j_raon-2017-0019_ref_019]^, and a high tumor burden.^[@j_raon-2017-0019_ref_013]^ Factors that account for the difference in the level of fluorescence in individual tumors remain to be clearly identified.

The aim of this study was to identify the factor(s), including MRI observations and genetic factors, with the greatest influence on intraoperative 5-ALA-induced fluorescence in patients with diffuse gliomas.

Patients and methods {#j_raon-2017-0019_s_002}
====================

Patient population {#j_raon-2017-0019_s_002_s_001}
------------------

The Research Ethics Committee of the Faculty of Medicine, University of Miyazaki, approved this study; prior informed consent for inclusion in the study was obtained from all patients. They underwent tumor removal at Miyazaki University Hospital during the period from January 2014 to December 2015. We collected 71 consecutive glioma patients. Our inclusion criteria were surgery under 5-ALA-induced fluorescence guidance, a preoperative MRI evaluation, and a histological diagnosis of astrocytic or oligodendroglial tumors based on the WHO 2007 classification.^[@j_raon-2017-0019_ref_020]^ Excluded were patients with WHO grade I tumors and/or needle biopsy only. In patients who had undergone surgical resection more than once during the period, data from the first resection were used. Of the 71 patients, 60 (35 men, 25 women; age range 6-80 years, mean age 60.7 years) with astrocytic or oligodendroglial tumors fulfilled our selection criteria; 54 (90.0%) harbored newly diagnosed gliomas. The patient characteristics, histological diagnosis, and tumor location are shown in [Table 1](#j_raon-2017-0019_tab_001){ref-type="table"}. Of the included patients, 35 (58.3%) had WHO grade IV, 17 (28.3%) WHO grade III, and 8 (13.3%) had WHO grade II gliomas. The tumor location was the frontal lobe (22 patients, 36.7%), followed by the temporal lobe (9 patients, 15.0%). In 8 patients (13.3%) the tumor was centrally located in the basal ganglion, corpus callosum, and brain stem; none of the tumors were occipital.

###### 

Clinical characteristics of 60 patients with diffuse gliomas

  Characteristics                        No. of Patients (%)
  -------------------------------------- ---------------------
  Number of patients                     60 (100)
  Sex                                    
   Male                                  35 (58.3)
   Female                                25 (41.7)
  Age (yrs)                              
   Average ± SD                          60.7 ± 15.4
   Median                                62.5
   Range                                 6 - 80
  Tumor grades and subtypes (WHO 2007)   
  **Grade II**                           **8 (13.3)**
   Astrocytoma                           2 (3.3)
   Oligoastrocytoma                      3 (5.0)
   Oligodendroglioma                     3 (5.0)
  **Grade III**                          **17 (28.3)**
   Anaplastic astrocytoma                2 (3.3)
   Anaplastic oligoastrocytoma           3 (5.0)
   Anaplastic oligodendroglioma          12 (20.0)
  **Grade IV**                           **35 (58.3)**
  Localization                           
   Frontal                               22 (36.7)
   Fronto-temporal                       2 (3.3)
   Temporal                              9 (15.0)
   Temporo-parietal                      5 (8.3)
   Temporal & insular                    2 (3.3)
   Parietal                              4 (6.7)
   Parieto-occipital                     2 (3.3)
   Occipital                             0 (0)
   Insular                               4 (6.7)
   Central                               8 (13.3)
   Cerebellar                            2 (3.3)
  Tumor Status                           
   Primary                               54 (90.0)
   Recurrence                            6 (10.0)

Preoperative MRI {#j_raon-2017-0019_s_002_s_002}
----------------

All preoperative MRI studies were performed within a week before surgery on a 3 Tesla scanner (Magnetom Verio; Siemens, Erlangen, Germany). T1- and T2-weighted- (T1W, T2W), and contrast-enhanced T1W axial images were used for analysis. The images were assessed consensually by two neuroradiologists blinded to the genotype and the 5-ALA-induced fluorescence of each lesion. They used methods described elsewhere^[@j_raon-2017-0019_ref_021]^ to qualitatively assess the following findings: a sharp or indistinct tumor border, homogeneous or heterogeneous signal intensity throughout the tumor on T1W and T2W images, and the presence or absence of contrast enhancement on contrast-enhanced T1W images [(Figure 1)](#j_raon-2017-0019_fig_001){ref-type="fig"}. Identification of the predominant characteristics of individual tumors was based on the readers' judgment of the tumor border and signal heterogeneity.

![Comparison of tumor characteristics on MRI scans. Axial T2W images showing a mass with **(A)** a smooth and **(B)** an indistinct tumor border in the left frontal lobe, **(C)** homogeneous intensity in the right frontal lobe, and **(D)** heterogeneous intensity in the left thalamus. Axial gadolinium-enhanced T1W images show that **(E)** the tumor lacks contrast enhancement in the right frontal lobe and is **(F)** contrast-enhanced in the left parietal lobe.](raon-51-142-g001){#j_raon-2017-0019_fig_001}

Surgical procedure {#j_raon-2017-0019_s_002_s_003}
------------------

5-ALA (20 mg/kg) was orally administered 3 hours before surgery. For the operation we used an OPMI Pentero instrument (Zeiss, Oberkochen, Germany) equipped with BLUE 400 for visualizing fluorescence and for neuro-navigation. All resections were performed with navigational guidance using contrast-enhanced axial, coronal, and sagittal T1W- or fluid-attenuated inversion recovery (FLAIR) images. The targets for tissue sampling were selected by choosing contrast-enhanced lesions and neuronavigation, or the tumor center of high-intensity lesions on FLAIR images. Fluorescence was checked repeatedly under our modified neurosurgical microscope by switching between white- and blue-violet excitation light in different areas of the lesion during each procedure. Fluorescence was categorized subjectively by two operating surgeons; a 3^rd^ surgeon confirmed their judgment by reviewing a movie obtained intraoperatively. Fluorescence was categorized as non-visible (negative) and visible (positive).^[@j_raon-2017-0019_ref_019],[@j_raon-2017-0019_ref_022]^ Positive fluorescence included mild (pink) and robust brightness (lava-like orange)^[@j_raon-2017-0019_ref_018]^ [(Figure 2)](#j_raon-2017-0019_fig_002){ref-type="fig"}.

![Appearance of the tumor cavity under the surgical microscope. **(A-B)** Violet-blue light excitation yielding visible 5-ALA fluorescence. Note robust (lava-like orange) **(A)** and mild (pink) brightness **(B)**. **(C)** No 5-ALA fluorescence is visualized in the tumor cavity.](raon-51-142-g002){#j_raon-2017-0019_fig_002}

Pathological diagnosis {#j_raon-2017-0019_s_002_s_004}
----------------------

To diagnose the tumors histopathologically, neuropathologists used the 2007 WHO classification of central nervous system tumors.^[@j_raon-2017-0019_ref_020]^ They were blinded to intraoperative 5-ALA fluorescence. Tumor cell proliferation was assessed immunohistochemically using MIB-1 antibody (anti-Ki-67, 1:50; DAKO, Hamburg, Germany). The highest density of Ki-67 immunopositive cells was evaluated in hot spots. The percentage of immunolabeled tumor cell nuclei was expressed as the MIB-1 labeling index.

IDH1 mutation analysis {#j_raon-2017-0019_s_002_s_005}
----------------------

IDH1 mutation was confirmed by immunohistochemical analysis using R132H antibody^[@j_raon-2017-0019_ref_023]^ or by direct sequencing. Immunostaining was according to the manufacturer's protocol. Briefly, formalin-fixed paraffin-embedded tissue was sliced into 2-μm sections and dried at 42ºC for 3 hours. Deparaffinization was with xylene, rehydration was by submerging the tissue samples in graded series of ethanol (100% to 70%, decreased in 10% steps). Phosphate-buffered saline (PBS) was used for washing. For antigen retrieval, slides were pretreated by steaming with citric acid buffer (pH 6.0) for 20 min in an autoclave. The sections were then treated with 10% H~2~O~2~ for 10 min at room temperature to block endogenous peroxidase activity. After washing in 3 changes of PBS for 5 min, the sections were immunostained with monoclonal anti-human IDH1-R132H antibody (1:20 dilution, H09, Dianova, Hamburg, Germany) diluted with PBS, and incubated at 4ºC overnight. After being washed in 3 changes of PBS buffer, the tissues were covered by anti-mouse specific second antibody administered in 1 - 3 drops per slide (Dako EnVision, Hamburg, Germany), and held for 30 min at room temperature. After being washed in 3 changes of PBS buffer, the staining reaction was performed by covering the tissue with a prepared 3, 3'-diaminobenzine (DAB) chromogen solution (1 drop of DAB chromogen for every 1000 μl of PBS). This was followed by incubation for approximately 40 sec to allow for proper brown color development. A definite cytoplasmic immunoreaction product was scored as staining cells. Staining was scored on a two-grade scale as negative (no or \< 10% staining), and as positive (\> 10% positively stained cells).

Direct DNA sequencing was as previously described.^[@j_raon-2017-0019_ref_023],[@j_raon-2017-0019_ref_024]^ IDH1 genomic DNA was isolated from frozen tissue samples with a QIAamp DNA Mini Kit (QIAGEN, Tokyo, Japan). A spanning 90-base pair (bp) fragment was identified with the sense primer IDH1 (forward: 5'-GGCTTGTGAGTGGATGGGTA-3') and the antisense primer IDH (reverse: 5'-GCAAAATCACATTATTGCCAAC-3'). The 25-μl reaction mixture contained 50 ng of tumor genomic DNA, 1 μl of each forward and reverse primer (10 μM), 12.5 μl of GoTaq Hot Start Green Master Mix (Promega K.K., Tokyo, Japan), and an amount of deionized water to obtain a total volume of 25 μl. Genomic DNA was subjected to polymerase chain reaction (PCR) amplification, initial denaturation at 95º for 2 min, and 35 cycles of amplification consisting of denaturation at 95º for 30 sec, annealing at 58º for 30 sec, and extension at 72º for 20 sec. Final extension was performed at 72º for 5 min. The 100-bp PCR amplification products were confirmed by 2% agarose gel electrophoresis.

The sequence reactions were performed by using a Big Dye Terminator v1.1 Cycle Sequencing Kit (Thermo Fisher Scientific K.K., Yokohama, Japan) in a 20-μl reaction mixture comprised of 1 μl of the 100-bp PCR products, 4 μl of PCR buffer, 2 μl of the forward primer (5 μM), 12 μl of deionized water and 1 μl of Big Dye Terminator Ready Reaction Mix. Initial denaturation was performed at 96º for 1 min and 25 cycles of amplification (denaturation at 96º for 30 sec, annealing at 50º for 5 sec, and extension at 60º for 4 min). Sequencing products were immediately submitted to direct sequencing on an ABI PRISM 310 Genetic Analyzer (Thermo Fisher Scientific K.K., Yokohama, Japan).

Fluorescence *in situ* hybridization (FISH) {#j_raon-2017-0019_s_002_s_006}
-------------------------------------------

FISH analysis of 1p19q loss of heterozygosity (LOH) was performed on formalin-fixed paraffin-embedded 5-μm tissues^[@j_raon-2017-0019_ref_025]^ prepared for dual-probe hybridization with Vysis LSI FISH Probe according to the manufacturer's instructions (Abbott Japan Co. Ltd.). 1p36/1q25 and 19q13/19p13 dual-color probe sets were used for locus-specific 1p and 19q analysis, respectively, following the manufacturer's instructions (Abbott Japan). Nuclei were counterstained with 4,6-diamidino-2 phenylindole (DAPI).

Analysis of MGMT promoter methylation {#j_raon-2017-0019_s_002_s_007}
-------------------------------------

Analysis of the methylation status of the MGMT promoter was performed by bisulfite modification and subsequent methylation-specific PCR assay using previously described primers.^[@j_raon-2017-0019_ref_008]^ The primer sequences for the unmethylated reaction were forward: 5'-TTTGTGTTTTGATGTTTGTAGGTTTTGT-3' and reverse: 5'-AACTCCACACTCTTCCAAAAA CAAAACA-3'. Sequences for the methylated reaction were forward: 5'-TTTCGACGTTCGTAGG TTTTCGC-3' and reverse: 5'-GCACTCTTCCG AAAACGAAACG-3'. The PCR conditions were 35 cycles of 30 sec each at 95º, and 60º, and 60 sec at 72º; the PCR products were electrophoresed on 15% polyacrylamide gels as previously described.^[@j_raon-2017-0019_ref_026]^

Statistical analysis {#j_raon-2017-0019_s_002_s_008}
--------------------

All numeric data were reported as the mean ± standard deviation. The positive predictive value (PPV) of 5-ALA fluorescence for high-grade gliomas was calculated as the number of 5-ALA fluorescence-positive high grade gliomas / number of all 5-ALA fluorescence-positive tumors. Its negative predictive value (NPV) was calculated as the number of 5-ALA fluorescence-negative low-grade gliomas (WHO grade II) / number of all 5-ALA fluorescence-negative tumors. The diagnostic accuracy of 5-ALA fluorescence for high-grade gliomas was calculated as the number of 5-ALA fluorescence-positive high-grade gliomas plus the number of 5-ALA fluorescence-negative low grade gliomas / the number of all tumors.

Univariate and multivariate logistic regression analyses were used to identify clinical characteristics and genetic- and imaging features associated with the 5-ALA-induced fluorescence of the lesions. Univariate analysis was with the χ^2^~-~, the Fisher exact-, or the Student *t*-test. Variables with p \< 0.05 by univariate analysis were used for multivariate analysis. In multivariate logistic regression analysis we computed the odds ratio (OR) and the accompanying 95% confidence interval (CI) using samples with non-visible fluorescence for reference. P values \< 0.05 were considered statistically significant. All statistical analyses were performed with SPSS software (version 23; IBM SPSS, Chicago IL, USA).

Results {#j_raon-2017-0019_s_003}
=======

Intraoperative 5-ALA fluorescence {#j_raon-2017-0019_s_003_s_001}
---------------------------------

Among the 60 tumors, 42 (70%) were 5-ALA fluorescence-positive; the others were negative. Of the 8 WHO grade II gliomas, 2 were positive, as were 9 of 17 (53%) WHO grade III and 31 (89%) of 35 grade IV gliomas [(Table 2)](#j_raon-2017-0019_tab_002){ref-type="table"}. For high-grade gliomas, the PPV of 5-ALA fluorescence was 95.2%; the NPV was 33.3%, and diagnostic accuracy was 76.7%.

###### 

5-aminolevulinic acid-induced fluorescence (5-ALA) in 60 diffuse gliomas

  5-ALA fluorescence   WHO grade II   WHO grade III   WHO grade IV
  -------------------- -------------- --------------- --------------
  Positive             2/8 (25 %)     9/17 (53 %)     31/35 (89%)
  Negative             6/8 (75 %)     8/17 (47 %)     4/35 (11%)

As shown in [Table 3](#j_raon-2017-0019_tab_003){ref-type="table"}, among the 60 diffuse gliomas, 13 (22%) harbored IDH1 mutations. These were more often seen in grade II (4/8, 50%) and grade III gliomas (7/17, 41%) than in glioblastomas (2/35, 6%). Of the 13 tumors with IDH1 mutations, 2 (15%) manifested visible fluorescence, the other 11 did not.

###### 

Relationsh ip between 5-aminolevulinic acid-induced fluorescence (5-ALA) status and clinical-pathologic features

  Clinical-pathologic features   Patients with visible fluorescence (n=42)   Patients with no visible fluorescence (n=18)   P value   χ^2^, Fisher, or Student t test
  ------------------------------ ------------------------------------------- ---------------------------------------------- --------- ---------------------------------
  Age (years)                                                                                                                         
  Average ± SD                   62.4 ± 16.4                                 56.7 ± 12.5                                    0.16      \-
  IDH1 mutation                                                                                                             \<0.001   23.57
  Positive                       2                                           11                                                       
  Negative                       40                                          7                                                        
  1p19q LOH                                                                                                                 0.003     10.22
  Positive                       5                                           9                                                        
  Negative                       37                                          9                                                        
  MGMT methylation                                                                                                          0.05      4.35
  Positive                       18                                          13                                                       
  Negative                       24                                          5                                                        
  MIB1 LI (%)                                                                                                                         
  Average ± SD                   38.5 ± 20.7                                 20.2 ± 22.8                                    0.007     \-
  Tumor margin                                                                                                              0.046     4.88
  Irregular                      27                                          6                                                        
  Smooth                         15                                          12                                                       
  T2 Heterogeneity                                                                                                          0.021     6.48
  Homo                           2                                           5                                                        
  Hetero                         40                                          13                                                       
  Contrast enhancement                                                                                                      0.002     11.71
  Positive                       41                                          12                                                       
  Negative                       1                                           6                                                        

Univariate analysis revealed a statistically significant association between 5-ALA fluorescence and the IDH1 status (mutated, non-mutated), 1p19q LOH, MIB-1, and the margin, heterogeneity, and contrast enhancement of the tumors (p \< 0.001, p = 0.003, p = 0.007, p = 0.046, p = 0.021, and p = 0.002, respectively); neither the patient age nor the MGMT methylation status was significantly associated. Multivariate analysis showed that the IDH1 status was the only independent, statistically significant factor related to 5-ALA fluorescence (p = 0.009) [(Table 4)](#j_raon-2017-0019_tab_004){ref-type="table"}. Using tissue samples with nonvisible fluorescence as the reference, we found that the OR (95% CI) for IDH1 wild type was 19.238 (1.39, 175.39). No other factors had a significant effect on 5-ALA fluorescence.

###### 

Multivariate analysis of significant factors from univariate analysis

  Factor                 P Value   Odds ratio   95% confidence interval
  ---------------------- --------- ------------ -------------------------
  IDH1 wild type         0.009     19.238       1.39, 175.39
  1p19q LOH              0.198     0.301        0.05, 1.87
  MIB-1 labeling index   0.157     1.033        0.99, 1.08
  Tumor margin           0.743     0.720        0.10, 5.15
  T2 heterogeneity       0.470     2.763        0.18, 43.44
  Contrast enhancement   0.345     4.107        0.22, 77.32

Discussion {#j_raon-2017-0019_s_004}
==========

In this study, we analyzed factors that influence the intraoperative visualization of gliomas by their 5-ALA-induced fluorescence. Our results demonstrate that the IDH1 status was the only independent, statistically significant factor related to 5-ALA fluorescence.

As in an earlier study^[@j_raon-2017-0019_ref_015]^, significantly more high- than low-grade gliomas exhibited 5-ALA fluorescence. Others^[@j_raon-2017-0019_ref_012],[@j_raon-2017-0019_ref_015],[@j_raon-2017-0019_ref_018],[@j_raon-2017-0019_ref_027]^ reported that MIB-1, an indicator of proliferation activity, and 5-ALA fluorescence were positively correlated. Widhalm *et al*.^[@j_raon-2017-0019_ref_027]^ who documented a significantly higher proliferation rate in the tumor area with- than without 5-ALA fluorescence found that visible 5-ALA fluorescence was correlated with a MIB-1 ≥10%. On the other hand, according to Lau *et al*.^[@j_raon-2017-0019_ref_018]^ 5-ALA intensity is a strong predictor of the degree of tumor cellularity in the most highly fluorescent areas but less predictive in areas with lower 5-ALA intensities. A significant difference in the contrast enhancement of fluorescing and nonfluorescing tissue on T1W MRI scans has been reported.^[@j_raon-2017-0019_ref_013]^ Our multivariate analysis showed that the IDH1 status was the only independent, significant factor affecting 5-ALA fluorescence.

Yang *et al*.^[@j_raon-2017-0019_ref_028]^ showed that in tumor cells the IDH mutation may lead to the accumulation of tricarboxylic acid (TCA) cycle metabolites. This results in the activation of the heme biosynthesis pathway that works to remove TCA metabolites. Inactivation of the TCA cycle by fumarate hydratase deficiency involves the biosynthesis and degradation of heme; this facilitates the use of accumulated TCA cycle metabolites and partial mitochondrial nicotinamide adenine dinucleotide (NADH) production.^[@j_raon-2017-0019_ref_029]^ A comparison of wild-type- and IDH1-mutant U87MG cell lines showed that mutated states of IDH1 are linked to enhance 5-ALA fluorescence.^[@j_raon-2017-0019_ref_024]^ Paradoxically, glioma tissue harboring IDH1 mutations accumulated high levels of 2-hydroxyglutarate (2HG) while the level of other TCA cycle metabolites, including alpha-ketoglutarate, malate, fumarate, succinate, and isocitrate, was not significantly altered.^[@j_raon-2017-0019_ref_030]^ These observations suggest that IDH1 mutant gliomas do not involve the activation of heme biosynthesis via activation of the TCA cycle.

The increased production of reactive oxygen species (ROS) was suggested to be implicated in human glioma tumorigenesis.^[@j_raon-2017-0019_ref_031]^ However, in embryonic brain cells from IDH1-mutant mice, intracellular ROS levels were dramatically reduced and the NADP^+^/NADPH ratio and catalase activity were increased.^[@j_raon-2017-0019_ref_032]^ We hypothesize that the acquisition of IDH1 mutations by low-grade gliomas upgrades their cell protection from oxidative injury. For example, heme oxygenase-1 (HO-1), one of the most important molecules affording protection against oxidative stress^[@j_raon-2017-0019_ref_033]^, is a microsomal and mitochondrial enzyme.^[@j_raon-2017-0019_ref_034]^ HO-1 catalyzes the oxidation of heme to biologically harmless products, *i*.*e*. carbon monoxide (CO), biliverdin (rapidly reduced to bilirubin), and ferrous iron. The treatment of melanoma cells with ALA during photodynamic therapy increased the accumulation of PPIX and concomitantly enhanced HO-1 expression.^[@j_raon-2017-0019_ref_035]^ Hagiya *et al*.^[@j_raon-2017-0019_ref_036]^ reported that the messenger RNA level of HO-1 and of ATP-binding cassette transporter G2 (ABCG2), a transporter of porphyrins from the cytoplasm to the extracellular space across the plasma membrane, was markedly increased when HepG2 cells were exposed to PPIX and visible light. These observations lead us to suspect that the difficulty in inducing fluorescence in IDH1-mutated gliomas is attributable to the establishment of a defense system against oxidative stress [(Figure 3)](#j_raon-2017-0019_fig_003){ref-type="fig"}.

![Schematic illustration of the relationship between heme synthesis and the IDH1 mutation. Thick arrows indicate metabolism activation, white arrows the activated enzymes or plasma membrane structures involved in porphyrin metabolism. ABCG2 transports porphyrins from the cytoplasm to the extracellular space. NADP^+^ levels increase during metabolization to bilirubin by heme. The IDH1 mutation may promote a defense system against ROS by activating catalase, HO-1, etc. The intracellular PPIX level is downregulated. (ABCG2 = ATP-binding cassette transporter G2; CO = carbon monoxide; FECH = ferrochelatase; HO-1 = heme oxygenase-1; PP = protoporphyrin; ROS = reactive oxygen species).](raon-51-142-g003){#j_raon-2017-0019_fig_003}

Although our study population was small, 22% of our 60 patients manifested IDH1 mutations. As in earlier studies^[@j_raon-2017-0019_ref_007],[@j_raon-2017-0019_ref_037],[@j_raon-2017-0019_ref_038]^, the incidence of the IDH1 mutation was highest in patients with WHO grade II gliomas. While there might be a difference in the frequency of IDH1 mutations between the Japanese and other populations, of our 8 WHO grade II gliomas, 75% were 5-ALA fluorescence-negative, a finding similar to that reported by others.^[@j_raon-2017-0019_ref_011],[@j_raon-2017-0019_ref_019]^ Interestingly, in both patients with 5-ALA fluorescence-positive grade II gliomas, IDH1 was wild-type. One of the patients died as a result of malignant transformation 24 months after the operation. Ballester *et al*.^[@j_raon-2017-0019_ref_039]^L. Y. Olar, A. Roy-Chowdhuri, S. Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas (L.Y.B. proposed that IDH1/2 wild-type gliomas be classified as molecular glioblastomas because, although the pathological diagnosis is low-grade glioma, the prognosis of patients with IDH1/2 wild-type gliomas is unfavorable. They also stated that the molecular subclassification of brain tumors identified important glioma subgroups whose prognosis is favorable and that mutations in IDH1/2, TP53, ATRX, and a 1p19q co-deletion suffice for the accurate molecular classification of diffuse gliomas. Even when the intraoperative pathological diagnosis is low-grade glioma, 5-ALA fluorescence positivity alerts to biological malignancy.^[@j_raon-2017-0019_ref_014]^

The PPV value of fluorescence as an indicator of high-grade gliomas was very high although the NPV was only 33%. Therefore, the possibility of high-grade glioma in the absence of intraoperative 5-ALA fluorescence cannot be excluded.

The IDH1 mutation status of diffuse gliomas is important as the mutation played a strong role in the intraoperative absence of 5-ALA fluorescence. The ability to identify the IDH1 status intraoperatively based on the presence or absence of fluorescence of tumor tissue may be useful for determining the appropriate degree of resection.

Our study has some limitations. First, as our study population was relatively small, our findings warrant validation studies in larger cohorts. Second, fluorescence was evaluated qualitatively and subjectively by experienced surgeons and quantitative assessment may yield more objective results.

Conclusions {#j_raon-2017-0019_s_005}
===========

Our study identified the IDH1 status as the only independent, statistically significant factor related to 5-ALA fluorescence. Further studies in a large population are required to clarify the association between the genetic status and the intraoperative 5-ALA-induced fluorescence of diffuse gliomas.
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